Skip to main content
SpringerLink
Log in

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The levels of serum beta-2 microglobulin (β2MG) are determined mainly from lymphoid tissue. To examine its prognostic value in Hodgkin lymphoma (HL), we conducted a retrospective analysis. We analyzed 67 patients with HL diagnosed and treated at seven institutes of the Yokohama City University Hematology Group between 1998 and 2011. The patients included 40 males and 27 females with a median age of 41 years (range 16–81 years). The HL subtypes were nodular sclerosis classical HL in 37 patients, mixed cellular classical HL in 23, lymphocyte-rich classical HL in 6, and nodular lymphocyte-predominant HL in 1. The 4-year overall survival (OS) rate of all 67 patients was 89 %. Patients with β2MG levels ≥2.5 mg/L (n = 18) showed inferior progression-free survival (PFS; 4-year PFS rate, 42 %) and inferior OS (4-year OS rate, 60 %) compared to patients who had β2MG levels <2.5 mg/L (n = 49; 4-year PFS rate, 87 %; 4-year OS rate, 98 %; P < 0.001). In multivariate analysis, only a serum β2MG level ≥2.5 mg/L was a significant adverse prognostic factor in regard to PFS (P = 0.04; relative risk 3.57). However, it was not significant prognostic factor for OS (P = 0.16) in the multivariate analysis. The serum β2MG level at diagnosis is a useful prognostic marker in patients with HL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–14.

    Article  PubMed  CAS  Google Scholar 

  2. Axdorph U, Sjöberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Björkholm M. Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin’s disease. Ann Oncol. 2000;11:1405–11.

    Article  PubMed  CAS  Google Scholar 

  3. Thompson CA, Maurer MJ, Cerhan JR, et al. Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol. 2011;86:998–1000.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Child JA, Spati B, Illingworth S, et al. Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas. Cancer. 1980;45:318–26.

    Article  PubMed  CAS  Google Scholar 

  5. Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

    Article  PubMed  Google Scholar 

  6. Decaux O, Renault A, Sébille V, et al. On behalf of the Intergroupe Francophone du Myéloma (IFM). Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients. Clin Lymphoma Myeloma Leuk. 2012;12:418–422.

  7. Constantinides IP, Pathouli C, Karvountzis G, et al. Serum beta 2 microglobulin in malignant lymphoproliferative disorders. Cancer. 1985;55:2384–9.

    Article  PubMed  CAS  Google Scholar 

  8. Johnson PW, Whelan J, Longhurst S, et al. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin’s lymphomas. Br J Cancer. 1993;67:792–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Federico M, Guglielmi C, Luminari S, et al. Prognostic relevance of serum β2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. Haematologica. 2007;92:1482–1488.

  10. Bairey O, Bar-Natan M, Shpilberg O. Early death in patients diagnosed with non-Hodgkin’s lymphoma. Ann Hematol. 2013;92:345–50.

    Article  PubMed  Google Scholar 

  11. Li ZM, Zhu YJ, Sun J, et al. Serum beta2-microglobulin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. Ann Hematol. 2012;91:1265–70.

    Article  PubMed  CAS  Google Scholar 

  12. Chronowski GM, Wilder RB, Tucker SL, et al. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer. 2002;95:2534–8.

    Article  PubMed  CAS  Google Scholar 

  13. Dimopoulos MA, Cabanillas F, Lee JJ, et al. Prognostic role of serum β2-microglobulin in Hodgkin`s disease. J Clin Oncol. 1993;11:1108–11.

    PubMed  CAS  Google Scholar 

  14. Albitar M, Vose JM, Johnson MM, et al. Clinical relevance of soluble HLA-I and β2-microglobulin levels in non-Hodgkin’s lymphoma and Hodgkin’s disease. Leuk Res. 2007;31:139–45.

    Article  PubMed  CAS  Google Scholar 

  15. Itoh K, Kinoshita T, Watanabe T, et al. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010;91:446–55.

    Article  PubMed  Google Scholar 

  16. Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. The prognostic significance of beta-2 microglobulin in patients with Hodgkin’s lymphoma. Haematologica. 2002;87:701–8.

    PubMed  CAS  Google Scholar 

  17. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  PubMed  Google Scholar 

  18. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

    Yuki Nakajima, Naoto Tomita, Yasufumi Ishiyama, Eri Yamamoto & Yoshiaki Ishigatsubo

  2. Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan

    Reina Watanabe, Hiroyuki Takahashi, Hirotaka Takasaki, Rika Sakai & Shigeki Motomura

  3. Department of Hematology, Yokosuka City Hospital, Yokosuka, Japan

    Daisuke Ishibashi

  4. Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan

    Megumi Itabashi & Satoshi Koyama

  5. Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

    Ayumi Numata, Hideyuki Kuwabara & Masatsugu Tanaka

  6. Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan

    Rika Kawasaki & Katsumichi Fujimaki

  7. Department of Hematology, Yamato Municipal Hospital, Yamato, Japan

    Chizuko Hashimoto

Authors
  1. Yuki Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoto Tomita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reina Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasufumi Ishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eri Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daisuke Ishibashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Megumi Itabashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satoshi Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroyuki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ayumi Numata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hirotaka Takasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rika Kawasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hideyuki Kuwabara
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masatsugu Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Chizuko Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Katsumichi Fujimaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Rika Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Shigeki Motomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Yoshiaki Ishigatsubo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuki Nakajima.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakajima, Y., Tomita, N., Watanabe, R. et al. Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. Med Oncol 31, 185 (2014). https://doi.org/10.1007/s12032-014-0185-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0185-3

Keywords

Search

Navigation